When was onpattro approved?

When was Onpattro (patisiran) approved?

Onpattro (patisiran) received FDA approval on August 10, 2018 for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis (hATTR amyloidosis) in adults [1].

Where did the approval happen (and for what indication)?

This approval was specifically for hATTR amyloidosis polyneuropathy, which is the condition Onpattro is used to treat [1].

Sources

1